**NEW for FY24**

Survivorship Research Award

Go to:
- Program Announcement
- General Application Instructions

**Grants.gov Funding Opportunity Number:** HT942524MRPSRA

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| **Survivorship Research Award** | The Principal Investigator (PI) must be an independent investigator at any career level. Individuals in a mentored position (e.g., postdoctoral fellows, clinical fellows) are not considered independent and are not eligible to be named as PI. PIs must be employed by or affiliated with an eligible organization, which includes foreign or domestic organizations, for-profit and nonprofit organizations and public entities. | • A letter of intent is required; an invitation to submit a full application is not required.  
• Supports a broad range of innovative and impactful survivorship research that has the intended outcome of improving the health and well-being of melanoma survivors (active- or post-treatment), their families and/or their caregivers.  
• Areas of survivorship research of interest to the MRP include, but are not limited to:  
  o Preservation of function and symptom management throughout treatment and beyond  
  o Psychological and social impacts of a melanoma diagnosis and treatment  
  o Treatment outcomes  
  o Health care delivery and disparity  
• The research team is required to collaborate with the melanoma consumer community (e.g., melanoma survivors, caregivers) to optimize research impact and translatability through inclusion of a melanoma consumer, partnership with a community-supporting organization or establishment of a community advisory board.  
• Clinical trials are allowed. | • The maximum allowable funding for the entire period of performance is $725,000 for direct costs.  
• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.  
• The maximum period of performance is 3 years. | Pre-Application (Letter of Intent): July 29, 2024 5:00 p.m. ET  
Application: August 26, 2024 11:59 p.m. ET |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| **Idea Award**                  | The PI must be at or above the level of Postdoctoral Fellow or equivalent.   | * **UPDATED FOR FY24** A letter of intent is required; an invitation to submit a full application is NOT required.*  
  PI's must be employed by or affiliated with an eligible organization, which includes foreign or domestic organizations, for-profit and nonprofit organizations and public entities. | * The maximum allowable funding for the entire period of performance is $400,000 for direct costs.  
  * Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
  * The maximum period of performance is 2 years. | Pre-Application (Letter of Intent):  
  **July 29, 2024 5:00 p.m. ET**  
  Application:  
  **August 26, 2024 11:59 p.m. ET** |
| **Melanoma Academy Scholar Award** | The PI (i.e., Scholar) must be within 7 years of their first faculty-level appointment as of the full application submission deadline.  
  A letter attesting to eligibility is required.  
  PI’s must be employed by or affiliated with an eligible organization, which includes foreign or domestic organizations, for-profit and nonprofit organizations and public entities. | * A letter of intent is required; an invitation to submit a full application is not required.*  
  * Supports the addition of new Scholars to the unique, interactive virtual Melanoma Academy that provides intensive mentoring, national networking, collaborations and a peer group for early-career melanoma investigators.  
  * Requires a Career Guide who is an experienced melanoma researcher with a history of obtaining melanoma research funding.  
  * The Career Guide is not required to be at the same institution as the Scholar.  
  * The Career Guide must be committed to participating in the Melanoma Academy, including serving in advisory roles as requested by Academy Leadership.  
  * Must address at least one of the FY24 MRP Focus Areas.  
  * Preliminary data are not required.  
  * Clinical trials are not allowed. | * The maximum allowable funding for the entire period of performance is $550,000 for direct costs.  
  * Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
  * The maximum period of performance is 3 years. | Pre-Application (Letter of Intent):  
  **July 29, 2024 5:00 p.m. ET**  
  Application:  
  **August 26, 2024 11:59 p.m. ET** |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Team Science Award | At least two and up to three PIs must partner in one multidisciplinary research study. PIs must be *independent* investigators at any career level. Individuals in a mentored position (e.g., postdoctoral fellows, clinical fellows) are *not* considered independent and are *not* eligible to be named as either Initiating or Partnering PI. Inclusion of at least one military, U.S. Department of Veterans Affairs or Early-Career Investigator is encouraged. PIs must be employed by or affiliated with an eligible organization, which includes *foreign or domestic organizations, for-profit and nonprofit organizations and public entities.* | *A letter of intent is required; an invitation to submit a full application is not required.*  
- Supports new or existing partnerships to address a research problem or question in a manner that would be unachievable through separate efforts.  
- Each PI should have equal intellectual input into the design and execution of the project.  
- Intended to fund a broad range of studies including, but not limited to:  
  - *Translational research* that leverages clinical samples from established biobanks, established biorepositories and/or ongoing or completed clinical trials  
  - *Data science research* involving the analysis of large and/or complex melanoma datasets  
  - Research that used *bioengineering approaches* to develop tools that assist in the detection, diagnosis, prognosis and/or treatment of melanoma  
  - Research seeking to better understand and/or reduce *inequities and disparities* that impact a person, their family and/or their caregiver’s ability to prevent, detect, manage and survive melanoma  
- Emphasis on multidisciplinary research and impact.  
- The research team is encouraged, but not required, to collaborate with the melanoma consumer community (e.g., melanoma survivors [active- or post-treatment], caregivers) to optimize research impact and translatability through inclusion of a melanoma consumer, partnership with a community-supporting organization or establishment of a community advisory board.  
- **Must** address at least one of the FY24 MRP Focus Areas.  
- **Preliminary data are required.** Preliminary data do not have to be derived from melanoma studies.  
- **Clinical trials are not allowed.** | *The maximum allowable funding for the entire period of performance is $1,500,000 for direct costs.*  
- Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
- The maximum period of performance is 3 years. | **Pre-Application (Letter of Intent):** July 29, 2024 5:00 p.m. ET  
**Application:** August 26, 2024 11:59 p.m. ET |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focused Program Award – Rare Melanomas</td>
<td>The PI must be an independent investigator at or above the level of Associate Professor (or equivalent). The Project Leader(s) for the complementary research project(s) must be an independent investigator(s) at or above the level of Assistant Professor (or equivalent). PIs must be employed by or affiliated with an eligible organization, which includes foreign or domestic organizations, for-profit and nonprofit organizations and public entities.</td>
<td><strong>A letter of intent is required; an invitation to submit a full application is not required.</strong> Applications may propose projects across the entire research spectrum (biology, etiology, prevention, diagnosis and detection, prognosis, treatment and quality of life) and must address a critical unmet need relevant to rare melanomas (uveal, acral, mucosal, pediatric, etc.). Supports a multidisciplinary research program of at least two but not more than three distinct but complementary projects addressing an overarching question relevant to rare melanomas. Individual research projects may range from exploratory, hypothesis-developing studies through clinical trials. The research team assembled by the PI should be highly qualified and multidisciplinary, with an identified Project Leader(s) for the complementary and synergistic research project(s). The research team is encouraged, but not required, to collaborate with the rare melanoma consumer community to optimize research impact and translatability through inclusion of a melanoma consumer, partnership with a community-supporting organization or establishment of a rare melanoma consumer community advisory board.</td>
<td>The maximum allowable funding for the entire period of performance is $2,000,000 for direct costs. The maximum period of performance is 4 years.</td>
<td>Pre-Application (Letter of Intent): July 29, 2024 5:00 p.m. ET Application: August 26, 2024 11:59 p.m. ET</td>
</tr>
</tbody>
</table>